Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

ADPT | Adaptive Biotechnologies Corporation

IndexRUT P/E- EPS (ttm)-1.33 Insider Own0.20% Shs Outstand144.40M Perf Week-16.34%
Market Cap751.48M Forward P/E- EPS next Y-1.01 Insider Trans-47.17% Shs Float141.96M Perf Month-22.00%
Income-190.90M PEG- EPS next Q-0.33 Inst Own89.30% Short Float / Ratio7.33% / 8.83 Perf Quarter-26.95%
Sales189.60M P/S3.96 EPS this Y4.90% Inst Trans-3.03% Short Interest10.41M Perf Half Y-35.33%
Book/sh2.74 P/B1.85 EPS next Y17.90% ROA-23.20% Target Price11.88 Perf Year-31.49%
Cash/sh2.81 P/C1.80 EPS next 5Y21.60% ROE-43.10% 52W Range4.95 - 10.79 Perf YTD-33.64%
Dividend- P/FCF- EPS past 5Y-31.30% ROI-43.10% 52W High-53.01% Beta1.26
Dividend %- Quick Ratio4.80 Sales past 5Y37.00% Gross Margin64.10% 52W Low2.42% ATR0.36
Employees790 Current Ratio5.00 Sales Q/Q11.90% Oper. Margin- RSI (14)29.41 Volatility7.29% 5.76%
OptionableYes Debt/Eq0.32 EPS Q/Q9.40% Profit Margin- Rel Volume1.07 Prev Close5.18
ShortableYes LT Debt/Eq0.32 EarningsAug 02 AMC Payout- Avg Volume1.18M Price5.07
Recom2.10 SMA20-18.25% SMA50-25.01% SMA200-34.24% Volume1,259,376 Change-2.12%
Date Action Analyst Rating Change Price Target Change
Jul-05-23Resumed JP Morgan Overweight $15
Jan-05-23Initiated Scotiabank Sector Outperform $15
Dec-21-22Upgrade Piper Sandler Neutral → Overweight $7.50 → $14
Aug-25-22Initiated Credit Suisse Underperform $8
Jun-03-22Initiated Piper Sandler Neutral $7.50
Feb-16-22Reiterated JP Morgan Overweight $75 → $50
Feb-16-22Reiterated Goldman Neutral $54 → $21
Feb-16-22Reiterated BTIG Research Buy $35 → $30
Feb-16-22Reiterated BofA Securities Buy $40 → $32
Oct-15-21Resumed Cowen Outperform
Jul-22-19Initiated BofA/Merrill Buy $45
Sep-13-23 07:30AM
Aug-30-23 04:30PM
Aug-28-23 11:53PM
Aug-24-23 10:29AM
Aug-02-23 05:35PM
04:30PM Loading…
Jul-29-23 12:12AM
Jul-19-23 08:52AM
Jul-10-23 04:05PM
Jun-24-23 03:19PM
Jun-16-23 05:02PM
Jun-02-23 10:15AM
May-29-23 08:08AM
09:45AM Loading…
May-26-23 09:45AM
May-24-23 04:05PM
May-23-23 09:54AM
May-15-23 07:50AM
May-12-23 08:00AM
May-09-23 07:30AM
May-04-23 09:13AM
May-03-23 05:25PM
Apr-27-23 10:02AM
Apr-26-23 10:02AM
Apr-25-23 04:05PM
Apr-24-23 09:40AM
Apr-18-23 12:10PM
Apr-12-23 07:30AM
04:05PM Loading…
Apr-06-23 04:05PM
Mar-29-23 04:20PM
Mar-27-23 09:40AM
Mar-16-23 11:41AM
Mar-10-23 10:42AM
Mar-09-23 09:55AM
Feb-28-23 11:11AM
Feb-27-23 04:05PM
Feb-24-23 11:52AM
Feb-21-23 09:55AM
Feb-14-23 05:55PM
Jan-30-23 07:21AM
Jan-23-23 04:05PM
Jan-10-23 09:00AM
Dec-27-22 04:05PM
Dec-20-22 06:14AM
Dec-10-22 10:00AM
Dec-05-22 07:30AM
Dec-01-22 07:30AM
Nov-21-22 04:05PM
Nov-03-22 06:35PM
Oct-11-22 08:05AM
Oct-05-22 04:05PM
Sep-15-22 06:48AM
Sep-14-22 05:22PM
Sep-12-22 08:30AM
Sep-02-22 08:00AM
Aug-14-22 11:13AM
Aug-04-22 12:00AM
Aug-03-22 05:35PM
Aug-02-22 10:07AM
Jul-28-22 10:02AM
Jul-27-22 10:01AM
Jul-18-22 06:56AM
Jul-08-22 04:05PM
Jun-16-22 12:49PM
Jun-15-22 07:30AM
Jun-10-22 05:00PM
Jun-03-22 10:09AM
Jun-02-22 04:10PM
May-31-22 11:42AM
May-26-22 08:00AM
May-13-22 10:35AM
May-04-22 10:30PM
May-02-22 04:05PM
Apr-05-22 04:30PM
Mar-31-22 11:16AM
Mar-25-22 04:54PM
Mar-22-22 10:10AM
Mar-11-22 12:43PM
Mar-10-22 10:15AM
Mar-09-22 10:37AM
Mar-02-22 04:05PM
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer and autoimmune disorders. It offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SOOD NITINChief Commercial Officer, MRDAug 08Sale6.5410,55068,997214,808Aug 08 04:53 PM
SOOD NITINChief Commercial Officer, MRDAug 07Sale6.785,65238,321225,358Aug 08 04:53 PM
PETERSON TYCHOChief Financial OfficerJun 20Option Exercise7.30134,961985,215534,180Jun 21 05:32 PM
PETERSON TYCHOChief Financial OfficerJun 20Sale8.14134,9611,098,583399,219Jun 21 05:32 PM
PETERSON TYCHOChief Financial OfficerJun 15Option Exercise7.3014,328104,594413,547Jun 20 05:41 PM
PETERSON TYCHOChief Financial OfficerJun 15Sale8.5370,000597,100399,219Jun 20 05:41 PM
PETERSON TYCHOChief Financial OfficerJun 02Sale7.1638,000272,080454,891Jun 06 04:23 PM
ADAMS R MARKChief Operating OfficerApr 11Sale8.632,30819,918175,361Apr 12 06:04 PM
ADAMS R MARKChief Operating OfficerApr 10Sale8.508176,944177,669Apr 12 06:04 PM
GRIFFIN MICHELLE RENEEDirectorMar 27Sale8.492,34119,87820,627Mar 29 05:01 PM
ADAMS R MARKChief Operating OfficerMar 07Sale8.6017,155147,533178,486Mar 08 08:03 PM
Taylor Stacy LSVP and General CounselMar 07Sale8.6013,387115,128139,678Mar 08 08:04 PM
SOOD NITINChief Commercial Officer, MRDMar 07Sale8.609,81384,392231,010Mar 08 08:01 PM
RUBINSTEIN JULIEPresidentMar 06Sale8.5722,668194,265336,824Mar 08 08:01 PM
BENZENO SHARONChief Commercial Ofc Imm MedMar 06Sale8.5711,749100,689223,826Mar 08 08:02 PM
LO FRANCISChief People OfficerMar 06Sale8.576,81658,413168,469Mar 08 08:04 PM
SOOD NITINChief Commercial Officer, MRDMar 06Sale8.576,66157,085240,823Mar 08 08:01 PM
ADAMS R MARKChief Operating OfficerMar 06Sale8.576,52955,954195,641Mar 08 08:03 PM
Taylor Stacy LSVP and General CounselMar 06Sale8.575,49147,058153,065Mar 08 08:04 PM
PISKEL KYLEPrincipal Accounting OfficerMar 06Sale8.573,52930,24687,564Mar 08 08:04 PM
HERSHBERG ROBERTDirectorFeb 02Option Exercise0.4553,00023,85061,193Feb 03 05:00 PM
ADAMS R MARKChief Operating OfficerJan 10Sale8.582,13018,275113,518Jan 11 06:00 PM
ADAMS R MARKChief Operating OfficerJan 09Sale8.509958,458115,648Jan 11 06:00 PM
PISKEL KYLEPrincipal Accounting OfficerNov 16Sale8.879598,50646,706Nov 17 06:00 AM
SOOD NITINChief Commercial Officer, MRDNov 01Sale8.0031,066248,528114,505Nov 01 09:00 PM
ADAMS R MARKChief Operating OfficerOct 10Sale7.132,28416,285116,643Oct 11 06:00 PM
ADAMS R MARKChief Operating OfficerOct 07Sale7.618416,400118,927Oct 11 06:00 PM